Sensyne Health Ltd, which is set to list on AIM on August 17, said on Wednesday that it has signed an exclusive licence agreement for a digital health software product, Support-HF, with the University of Oxford and Oxford University Hospitals NHS Foundation Trust.
The Oxford-based firm, which uses artificial intelligence (AI) to develop medicines said Support-HF will help patients and clinicians in managing heart failure and curate data for medical research using Clinical AI.
The company said it also plans to develop a cloud-based scalable version of Support-HF to help support the management of heart failure at home.
The collaboration, which was established in July last year, creates a pathway for the commercial development of digital health innovations invented and clinically validated by the University and the Trust, Sensyne said.
In a statement on the group’s website, Sensyne founder and chief executive Paul Drayson commented: "Support HF has the potential to make significant improvements in the care of patients suffering from heart failure and is a further example of the pipeline of digital health innovations coming out of research at Oxford.”
Drayson, a peer and a former Labour government minister in the 2000’s added: "Sensyne Health will now develop the product so that it may be deployed more widely across the NHS and then internationally.”